Biography
Fred Hutchinson Cancer Research Center, Seattle WA (1999)
University of Washington (Medical Oncology, 1996)
Mayo Graduate School of Medicine (Internal Medicine, 1993)
University of California, Irvine (1990)
Personal Statement
My research interest is focused on the development of novel therapeutic agents for the treatment of hematological malignancies. Towards this aim, I am serving in three different leadership positions:
1) I am the director of the UNM Bone Marrow Transplant and Cell Therapy Program, which has brought autologous hematopoietic stem cell transplant technology to New Mexico, with the intent of introducing allogeneic stem cell transplant and both CAR-T therapy in the near future. Our program is currently undergoing FACT accreditation to further this aim.
2) I am the leader of the Hematology Clinical Working Group, a committee which reviews and prioritizes all clinical trials for hematological malignancies at UNM and affiliate NCORP community sites.
3) My laboratory uses preclinical models to identify novel therapeutic targets for hematological malignancies, and to test the therapeutic efficacy of novel agents. We have expertise both the development of novel targeted and transgenic mice, as well as human tumor xenograft models to elucidate the oncogenic interactions of genes and carcinogenic compounds, in order to understand their potential risks and pathogenic mechanisms.
In addition to this basic science work, my laboratory is interested in the fundamental processes of hematopoiesis and the development of novel cell therapeutic agents. We assist the Cancer Center in validating autologous stem cell products that have been transported from our processing facility prior to stem cell transplantation, and we are interested in contributing to the creation of a Cell Therapy Developmental laboratory which would advance the therapeutic transplational capabilities of the UNM BMT program.
Areas of Specialty
Medical Oncologist
Hematological Malignancies (Leukemia, Lymphoma, and Myeloma)
Bone Marrow Transplant & Cellular Therapy Expert
Education
Medical School: University of California, Irvine (1990)
Residency: Mayo Graduate School of Medicine (Internal Medicine, 1993)
Fellowship: University of Washington (Medical Oncology, 1996)
Certifications
Bone marrow transplant expert
Current Member of American Society of Hematology
Member of American Society for Blood and Marrow Transplantation
Fellow of the American College of Physicians
Internal Medicine (1993 2003)
Medical Oncology (1996 current)
Achievements & Awards
Memberships: Current Member of American Society of Hematology | Member of American Society for Blood and Marrow Transplantation | Fellow of the American College of Physicians
Gender
Male
Languages
- English
Research and Scholarship
1. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, Pereira SE, Nash RA, Mielcarek M, Fero ML, Warren EH, Sanders JE, Storb RF, Appelbaum FR, Storer BE, Martin PJ. Blood. 2011 Mar 17;117(11):3214-9. PMID: 21263156.
2. The miR-106a~363Xpcl1 miRNA cluster induces murine T cell lymphoma despite transcriptional activation of the p27Kip1 cell cycle inhibitor. Kuppers DA, Schmitt TM, Hwang HC, Samraj L, Clurman BE, Fero ML. Oncotarget. 2017 Apr 7;8(31):50680-50691. PMID: 28881594.
3. Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia.Gronseth CM, McElhone SE, Storer BE, Kroeger KA, Sandhu V, Fero ML, Appelbaum FR, Estey EH, Fang M. Cancer. 2015 Sep 1;121(17):2900-8. PMID: 26033747.
4. Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells.Walkley CR, Fero ML, Chien WM, Purton LE, McArthur GA. Nat Cell Biol. 2005 Feb;7(2):172-8. PMID: 15654333.
5. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM. Cell. 1996 May 31;85(5):733-44. PMID: 8646781.